Mumbai, Aug 31 (IANS) Drug maker Wockhardt Ltd. said Thursday it had received approval from the US Food and Drug Administration (FDA) to market cefotaxime sodium injection, a broad-spectrum antibiotic used in treating a wide variety of infections in the US market.
The company's US subsidiary, Wockhardt USA Inc., will launch the antibiotic in the American market in the next few weeks, the company said in a statement in Mumbai Thursday.
'This is our second approval for sterile cephalosporins, and our sixth approval in the last eight months,' Wockhardt Chairman Habil Khorakiwala said.
'The rapid build-up of portfolio is helping us make our presence felt in the US, the world's largest pharmaceutical market,' Khorakiwala said.
Wockhardt markets 14 products in the US.
Cefotaxime sodium is manufactured at the US FDA certified sterile cephalosporin API (active pharmaceutical ingredient) facility at Ankleshwar and the injection is manufactured at the sterile formulation plant at Waluj. The processes for both API and the injection were developed in-house, the statement said.